This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. If you’re starting a weight loss journey, you might have ...
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
The Food and Drug Administration (FDA) has reaffirmed that Mounjaro and Zepbound are no longer in shortage following a ...
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.
Tirzepatide, the main ingredient in Mounjaro and Zepbound, is no longer in shortage, according to the U.S. Food and Drug ...
The U.S. Food and Drug Administration announced Thursday that the shortage of tirzepatide — the active ingredient in Eli ...
Tirzepatide is the active ingredient in Zepbound and in Eli ... Nordisk's two GLP-1s that are still on the FDA's drug shortage list. Many compounding pharmacies make unbranded versions of ...
This opened the door for pharmacies to offer custom-made versions with the same active ingredient, known as compounded ... per month for tirzepatide, compared to Zepbound's list price of $1,059.